AbCellera (Nasdaq: ABCL) today announced an additional purchase by the U.S. government from Eli Lilly and Company (Lilly) for bamlanivimab with etesevimab for administration together.
Read More
Immune Biosolutions Inc. is consolidating its biopharmaceutical transition, following the accelerated development of its activities. The company will focus its activities towards the discovery and development of immunotherapies for infectious diseases, inflammation and cancer. To propel Immune Biosolutions' growth in this new phase, the company is pleased to announce the appointment of Mr. Luc Paquet as Chief Executive Officer.
Read More
Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for parsaclisib, an investigational novel potent, highly selective, next-generation oral inhibitor of phosphatidylinositol 3-kinase delta (PI3Kδ), for the treatment of patients with relapsed or refractory follicular lymphoma (FL), marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL).
Read More
BioTalent Canada today announced the kickoff of a $1.15M research study titled Building Resiliency and Sustainability for the Bio-economy to Withstand Disruption. The project, funded by the Future Skills Centre, which wraps up in September 2022, will leverage lessons learned from the pandemic to ensure long-term sustainability within Canada’s bio-economy.
Read More
This Japanese study, in combination with final data from the global Phase 2/3 study of the vaccine candidate, will be used to support an application for regulatory approval in Japan by March of 2022.
Read More
AmorChem, BIOQuébec and CQDM, co-organizers of Sweet Pharma Day, are pleased to announce that HDAX Therapeutics is the winner of the 2021 edition. Sixteen Canadian startup companies (“Sweet 16”) selected by representatives from global pharma companies, made an elevator pitch in front of 150+ participants, who voted for HDAX Therapeutics as the winner of Sweet Pharma Day 2021 and of the $2,500 grand prize.
Read More
Life science stakeholders, in particular, can play a central role in addressing current challenges, while delivering significant economic benefits including investment and jobs.
Read More
Molecular Forecaster Inc. (MFI) is excited to announce it has secured funding to further develop its structure-based drug-design software, offer its research services, and expand into new niche drug targets.
Read More
Laurent Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing LAU-7b, a first-in-class pro-resolving drug candidate, reported today topline results from its Phase 2 RESOLUTION clinical trial in hospitalized COVID-19 patients.
Read More
Today, seven founding member organizations from the private, public, and not-for-profit sectors announced the establishment of the Inclusive Life Sciences Collaboration (Collaboration). The Collaboration aims to create a community of like-minded individuals and organizations committed to creating inclusive organizational cultures across the life sciences sector.
Read More
Acasti Pharma Inc. today provided a business update and announced that the Nasdaq Stock Market (“Nasdaq”) has confirmed to Acasti that the Company has regained compliance with Nasdaq’s minimum bid price requirement.
Read More
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today announced positive findings from a preplanned administrative interim analysis of the ongoing Phase 2b SOOTHE trial of BLU-5937, the Company’s highly selective P2X3 antagonist, in patients with refractory chronic cough (“RCC”).
Read More
August 30, 2021, Montréal, Canada – Vantage BioTrials, a full service Contract Research Organization (CRO), is proud to have successfully managed, and completed approximately 12 months in advance, a Phase IV observational, multicentre, postmarketing study in adult patients with a clinical diagnosis of moderate-to-severe Hidradenitis suppurativa (HS).
Read More
MONTREAL, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Theratechnologies, Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today the publication of data from its preclinical research of TH1902 for the treatment of sortilin-positive triple negative breast cancer (TNBC) in the peer-reviewed journal Cancer Science, confirming the in vivo efficacy and safety of TH1902 against TNBC through a SORT1 receptor-mediated mechanism.
Read More
MONTREAL--(BUSINESS WIRE)--Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced that following the receipt of a No Objection Letter (NOL) from Health Canada on July 29, 2021, it has dosed the first volunteers with INV-202 in its first-in-human phase 1 clinical trial, which will evaluate the safety, tolerability and pharmacokinetics of this compound.
Read More
MONTRÉAL, Aug. 31, 2021 /CNW Telbec/ - CellCarta and Olink Proteomics AB announced today a strategic collaboration to offer Olink® Target 96 & Target 48 to pharmaceutical and biotech customers, advancing targeted protein biomarker quantification in clinical studies.
Read More
Montreal, Quebec, August 26, 2021 – Novartis Pharmaceuticals Canada Inc., in partnership with C2 International is hosting the first ever Biome Summit in Canada. A unique, collaborative multi-stakeholder platform, the Summit this year aims to address the pressing issue of cardiovascular disease across the country.
Read More
MONTREAL, Aug. 24, 2021 /CNW/ - Incyte (Nasdaq: INCY) today announced that Health Canada has granted a Notice of Compliance with conditions for Minjuvi® (tafasitamab), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, who are not eligible for autologous stem cell transplant (ASCT).
Read More
MONTRÉAL, Aug. 17, 2021 /CNW Telbec/ - NuChem Sciences, a drug discovery in chemistry contract research organization (CRO) located in Montréal, today announced the acquisition of OmegaChem of Lévis, Québec. As a result of this transaction, the new group formed by the two companies becomes Canada's largest CRO in drug discovery in chemistry.
Read More
MONTRÉAL, Aug. 10, 2021 /CNW/ - Today, the Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry, announced a major milestone in Canada's strategy to rebuild the biomanufacturing and life sciences sector. The Government of Canada has established a memorandum of understanding (MOU) with leading COVID-19 vaccine developer Moderna, Inc. to build a state-of-the-art mRNA vaccine production facility in Canada.
Read More